Stocks in Focus

Major Shareholder Buys Back Shares to Boost Shareholder Value… LabGenomics. Co., Ltd. Up 9% [Featured Stock]

Kwon Oh Seok
2026-07-15 09:30:14
[Edaily Reporter Kwon Oh Seok ] LabGenomics. Co., Ltd.(084650)’s stock price is surging in early trading. Buying interest appears to be surging following news that the company’s largest shareholder has begun purchasing additional shares to strengthen responsible management and enhance shareholder value.

According to MP Doctor on the 15th, LabGenomics. Co., Ltd. is trading at 712 won as of 9:23 a.m., up 9.37% from the previous trading day.
Earlier today, LabGenomics. Co., Ltd. issued a press release stating that its largest shareholder, Ruhagalacticos, had acquired an additional 1,240,100 shares of the company’s stock through on-market purchases. As a result, Luha Galacticos’ shareholding increased from 13,893,425 shares to 15,133,525 shares, and its ownership stake expanded from 18.7% to 20.38%. The total value of this purchase is approximately 1 billion won.
This purchase follows a 2 billion won on-market acquisition carried out last June. At that time, Luha Galacticos acquired an additional 1,893,891 shares, raising its ownership stake from approximately 16.2% to 18.7%.
Ruhagalacticos is a special purpose company (SPC) established by Ruhag PE, a private equity fund (PEF) manager. The largest shareholder’s consecutive increases in its stake are interpreted as reflecting confidence in LabGenomics. Co., Ltd.’s mid- to long-term growth potential and corporate value.
Previously, LabGenomics. Co., Ltd. announced last month that it had decided to implement a 5-to-1 stock consolidation. Through this measure, the company aims to adjust the number of outstanding shares to an appropriate level, mitigate the perception of the stock as a low-priced stock, and lay the groundwork for a more reasonable market valuation of its corporate value.

Economy

Corporation

IT·Science

Corporation

[ESMO 2026] Vaxcell-Bio Therapeutics: “CAR-MIL Shows 100% Survival Rate in Animal Trials… Compared to J&J’s Carvikt”

It has been confirmed that “VCB-1201,” a multiple myeloma cell therapy currently under development by Vaxcell-Bio Therapeutics(323990), achieved a 100% survival rate over 120 days in preclinical anima…
2026-10-28 11:01:02

IT·Science

"What Matters More Than an Apology Is the Company's Willingness to Absorb Losses"... The Formula for Restoring Trust Left by the SKT Hacking Incident

Experts have analyzed that for companies to restore customer trust eroded by security incidents, they must go beyond one-time apologies or compensation campaigns and proactively shoulder the risks and…
2026-10-28 11:34:49